Spike glycoprotein · SINGLE PROTEIN · Severe acute respiratory syndrome coronavirus 2
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Spike glycoprotein shows approved-linked disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 18 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P0DTC2. Start with COVID-19, then reuse UniProt P0DTC2 as the stable protein anchor across project notes and exports.
Start with COVID-19, then reuse UniProt P0DTC2 as the stable protein anchor across project notes and exports.
Spike glycoprotein shows approved-linked disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 18 linked drugs remain visible in the same block.
Start review with COVID-19 because it currently carries approved-linked support. Linked drugs include ADENOVIRUS TYPE 26 ENCODING SARS-COV-2 SPIKE GLYCOPROTEIN, ADINTREVIMAB, AMUBARVIMAB, BAMLANIVIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxySpike glycoprotein
Review this target as Spike glycoprotein, mapped to UniProt P0DTC2. Sequence length is 1273 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Spike glycoprotein as ChEMBL target CHEMBL4662936, mapped to UniProt P0DTC2. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Spike glycoprotein is the right protein anchor across sources, using UniProt P0DTC2 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why COVID-19 is currently framed as approved-linked support. It currently carries 18 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Spike glycoprotein |
| Target Type | SINGLE PROTEIN |
| Organism | Severe acute respiratory syndrome coronavirus 2 |
| UniProt | P0DTC2 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Spike glycoprotein |
| UniProt Accession | P0DTC2 |
| Component Type | Protein |
| Sequence Length | 1273 aa |
Spike glycoprotein
Review this target as Spike glycoprotein, mapped to UniProt P0DTC2. Sequence length is 1273 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Spike glycoprotein shows approved-linked disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block.
Start review with COVID-19 because it currently carries approved-linked support. Linked drugs include ADENOVIRUS TYPE 26 ENCODING SARS-COV-2 SPIKE GLYCOPROTEIN, ADINTREVIMAB, AMUBARVIMAB, BAMLANIVIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5088895 | 10.52 | Kd | 0.03 | Preclinical |
| CHEMBL5088125 | 7.89 | Kd | 13.0 | Preclinical |
| CHEMBL4869623 | 7.64 | Kd | 22.8 | Preclinical |
| CHEMBL5079992 | 7.54 | Kd | 29.0 | Preclinical |
| CHEMBL5085069 | 7.51 | Kd | 31.0 | Preclinical |
| CHEMBL330348 | 7.42 | IC50 | 38.0 | Preclinical |
| CHEMBL330348 | 7.42 | Kd | 37.9 | Preclinical |
| CHEMBL5093610 | 7.34 | Kd | 46.0 | Preclinical |
| CHEMBL5274408 | 7.0 | IC50 | 100.0 | Preclinical |
| CHEMBL5081573 | 6.99 | Kd | 102.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 38 | 37 | 5.8 |
| cell-based format | 6 | 6 | 6.4 |
| assay format | 3 | 10 | 5.4 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 2 | 2 | 5.2 |